Abstract: The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof.

Abstract: Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.

Abstract: Provided are an HPV chimeric protein and a use thereof. The HPV chimeric protein of the present invention comprises an HPV58 L1 protein or a mutant thereof and a polypeptide derived from a HPV16 L2 protein and inserted into a surface region of the HPV58 L1 protein or the mutant thereof, or consists of the polypeptide, wherein an amino acid sequence of the HPV58 L1 protein is as shown in SEQ ID No. 1 and an amino acid sequence of the HPV16 L2 protein is as shown in SEQ ID No. 2.

Abstract: The present disclosure provides use of a reagent for detecting retinol metabolites in preparation of a tool for diagnosing and/or treating pneumoconiosis, and relates to the technical field of biomedicine. The present disclosure verifies that retinol metabolism disturbance and all-trans retinoic acid (ATRA) deficiency are closely related to the pathogenesis of pneumoconiosis. Therefore, the present disclosure sets forth use of retinol and ATRA as biomarkers for screening the pneumoconiosis and use thereof in preparation of products related to the diagnosis of the pneumoconiosis; meanwhile, intervention of the pneumoconiosis with the ATRA can effectively delay the progression of the pneumoconiosis. Therefore, the present disclosure first sets forth use of the ATRA as a medicament for treating the pneumoconiosis.

Abstract: The present disclosure provides use of malic enzyme 2 (ME2) in preparation of a diagnostic reagent or a medicament for silicosis or pulmonary fibrosis-related diseases, and belongs to the technical fields of medical treatment and medicine. Research results of the present disclosure show that ME2 knockout significantly alleviates inflammatory response and fibrotic lesions in mice with silicosis. Based on the above research results, the present disclosure provides use of ME2 in treatment of pulmonary inflammatory responses and pulmonary fibrotic lesions of silicosis or pulmonary fibrosis-related diseases. Expression of ME2 is inhibited to alleviate the inflammatory response and fibrotic lesions of the silicosis, providing support for exploring a targeted drug for treating pulmonary inflammatory responses and pulmonary fibrosis of silicosis or pulmonary fibrosis-related diseases.

Abstract: The present disclosure provides use of an Fc?RIII inhibitor for treating pulmonary fibrosis, and belongs to the technical field of biomedicine. Results indicate that Fc?RIII mediates macrophage phagocytosis of silica particles, Fc?RIII knockout can effectively relieve pulmonary inflammatory response and fibrotic lesions in mice with silicosis, and further intratracheal administration of an anti-Fc?RIII antibody significantly delays disease progression of mice at fibrosis phase. Therefore, the present disclosure first sets forth that the Fc?RIII inhibitors can be used for treating pulmonary fibrosis, which is of importance to the screening of new drugs and provides a new idea for treatment of pulmonary fibrosis.

Abstract: The present disclosure is directed to methods of administering tetrandrine in combination with all-trans retinoic acid (ATRA) for treating pneumoconiosis. Administration of ATRA in combination with tetrandrine can effectively alleviate the progression of silicosis: impaired cardiopulmonary functions of mice with silicosis are improved significantly, including inspiratory capacity, quasi-static compliance, and right ventricular pressure; concentrations of inflammatory factors IL-1? and IL-6 in bronchoalveolar lavage fluids of mice with silicosis decrease, and the number of inflammatory cells is reduced; levels of fibrosis factors FN-1 and Col-I decrease, fibrous foci are reduced, and pathological degree is alleviated. Moreover, combination therapy with ATRA in combination with tetrandrine shows a superiority of combined administration in terms of cardiopulmonary function, inflammation and fibrosis, and exhibits a better effect than administration of tetrandrine alone.

Abstract: Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.

Abstract: Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.

Abstract: Disclosed are a heterogeneous stem cell population, a preparation method therefor, and the use thereof. Specifically, disclosed is a heterogeneous stem cell population, characterized in that stem cells in the heterogeneous stem cell population express stemness genes MYC, KLF4, GMNN, SOX2 and NANOG, and in the heterogeneous stem cell population, the ratio of stem cells expressing CD146 is 1%-50%.

Abstract: Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present disclosure can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.

Abstract: The present invention discloses a dual-drug co-delivery system, a preparation method therefor and use thereof, the dual-drug co-delivery system being prepared from raw materials comprising a block copolymer, Homoharringtonine and Doxorubicin hydrochloride. The dual-drug co-delivery system provided by the present invention has a stronger killing effect on various hematologic tumors and solid tumor cells, can provide a feasible drug delivery system for inhibiting tumor growth and leukemia treatment, and has broad prospects.

Abstract: A method for detecting pores on cell membrane using an atomic force microscope, comprising the steps of: providing cells; fixing the cells in place; and observing the cells by means of an atomic force microscope. The pores are present in the cell membrane or pass through the cell membrane. By means of the present method, the presence of pores in the cell membrane can be accurately observed, and the size and depth of the pores can be accurately determined.

Abstract: Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.

Abstract: The invention discloses a conjugate constructed by conjugating a HSP90 inhibitory peptide to cytotoxic agent via linker and use thereof in the preparing medicine for preventing and/or treating tumor. The mentioned conjugates possess triple anti-tumor effects including targeting delivery, chemotherapy and apoptosis-promotion, which can enhance the anti-tumor efficacy, reduce the dosage, and decrease the toxicity induced by accumulation of chemotherapeutics.

Abstract: The present invention discloses an application of clofoctol for manufacturing a pharmaceutical product for treating human neuroglioma. The clofoctol is a pharmaceutical product for treating an upper respiratory tract infection. The clofoctol exerts a significant and specific inhibition of a glioma stem cell activity relative to a human neuroglioma cell or a normal human astroglia, human embryonic kidney cell, and human neural stem cell. A glioma stem cell treated with the clofoctol exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma.

Abstract: A group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia are described.

Abstract: The present invention provides a humanized monoclonal antibody against extracellular domain of human death receptor 5, comprising a light chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 1, a heavy chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 2, and constant region derived from human antibody. The present invention also provides nucleotide sequence encoding said humanized monoclonal antibody, a recombinant eukaryotic expression vector, a process for preparing the humanized monoclonal antibody, and the composition and use therefore.

Abstract: The present invention provides a human Tim-3-Ig fusion protein which can block Tim-3 signal pathway, and said Ig fusion protein comprises Tim-3 protein, human Ig fragment, and the linking sequence therebetween. In the present invention, a human Tim-3-Ig gene is obtained by an artificial synthesis process; an expression vector containing the Tim-3-Ig gene is constructed; and the prepared Ig fusion protein is tested in an expression verification experiment, a binding activity experiment, a blocking activity experiment in different cell lines, and in vivo experiments in mice. The human Tim-3-Ig fusion protein prepared in the present invention can be used to treat immunological diseases caused by high expression of Tim-3.

Abstract: Provided are antigenic determinants of human death receptor DR5. The antigenic determinants have the amino acid sequence of LITQQDLAPQQRA (SEQ ID No. 7), wherein the core polypeptide is QDLAP (SEQ ID No. 1). The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine.